GCOM 2019
3RD GLOBAL CONFERENCE ON MYOSITIS

Conference Programme Overview

Wednesday, 27 March 2019
10:00 – 12:30 Pre-Congress Pathology Workshop: Make the diagnosis - difficult cases including morphology – A Amato (USA), A Mammen (USA), I Nishino (Japan)
12:30 – 14:00 Lunch
14:00 – 15:00 Welcome – O Benveniste (France), I Nishino (Japan) & W Stenzel (Germany)
General Lecture: Recent developments in therapeutic approaches for neuromuscular diseases – T Voit (UK)
15:00 – 16:30 I Sporadic Inclusion Body Myositis (sIBM) – T Lloyd (USA), J Zschüntzsch (Germany)
15:00 – 15:25 1: Muscle aging – M Kjaer (Denmark)
15:25 – 15:50 2: Pathogenic mechanisms connecting inherited and acquired inclusion body myopathy – C Weihi (USA)
15:50 – 16:30 3: Selected oral presentations
   Xenograft model of sporadic inclusion body myositis – K Britson (USA)
   Targeting highly differentiated effecter memory KLRG1+ cytotoxic T cells in inclusion body myositis – S Greenberg (USA)
   CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis – G Dzangué-Tchoupou (France)
16:30 – 17:15 Coffee Break
17:15 – 18:30 IIa Extramuscular (Neoplasia) – Y Allenbach (France), M de Visser (The Netherlands)
17:15 – 17:40 1: Lessons learnt from immune checkpoint inhibitor cardiovascular toxicities – J Moslehi (USA)
17:40 – 18:30 2: Selected oral presentations
   Overall and site-specific cancer risk before and after diagnosis of idiopathic inflammatory myopathies: Novel register data from 2002 to 2016 in Sweden – L Dani (Sweden)
   Immunization of dermamyositis-specific auto-antigen transcriptional intermediary factor (TIF1)-γ induces myositis in mice – N Okiyama (Japan)
   The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody positive dermamyositis – A Oldroyd (UK)
   Pruritonegic mediators in skin samples of patients with dermamyositis – A Vincze (Hungary)
18:30 Welcome Reception: Berlin history in a nutshell – J Marberg (Germany)

Thursday, 28 March 2019
08:30 – 10:00 IIb Extramuscular (Lung) – B Hervier (France), M Needham (Australia)
08:30 – 08:55 1: How to evaluate clinical outcomes of myositis-associated interstitial lung disease – M Kuwana (Japan)
08:55 – 09:20 2: Lungs as a trigger of autoimmunity: The role of environmental factors – L Klareskog (Sweden)
09:20 – 10:00 3: Selected oral presentations

www.gcom2019.com
High level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis – **Q Peng** (China)

Anti-MDA5 antibody-associated dermatomyositis: Three subgroups with different outcomes – **S Toquet** (France)

Risk stratification in patients with anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease treated initially with intensive combination regimen – **T Gono** (Japan)

10:00 – 11:15
Coffee Break and Exhibition
Poster Session I (P.001-044)
Dermatomyositis (P.001-024)
Extramuscular aspects in myositis (P.025-040)
Trials (P.041-044)

11:15 – 12:45
**III Treatment and Trials** – **B Feldman** (Canada), **O Landon-Cardinal** (Canada)

11:15 – 11:40
1: Bayesian statistics for rare diseases (from registries to clinical trials) – **L Biard** (France)

11:40 – 12:05
2: Trial readiness in rare diseases – **V Straub** (UK)

12:05 – 12:45
3: Selected oral presentations
  *Quantitative high throughput screening of small molecule libraries to inhibit interferon beta-stimulated major histocompatibility complex class I in myositis muscle – **T Kinder** (USA)*
  *Study of Tafacinibit in refractory dermatomyositis – **J Paik** (USA)*
  *A one-year study investigating the effect of specialised and intensive ADL training in patients with idiopathic inflammatory myopathies - preliminary results – **M Špiritović** (Czech Republic)*

12:45 – 14:00
Lunch

14:00 – 16:00
**Workshop for Young Physicians/Researchers**: Clinics & Research: Specificities in different countries. How to improve international collaborations? – **O Benveniste** (France), **H Chinoy** (UK), **L Christopher-Stine** (USA), **M Fujimoto** (Japan), **A Mammen** (USA), **I Nishino** (Japan), **W Stenzel** (Germany)

14:00 – 16:00
**Patient-Centered Workshop** – **J Schmidt** (Germany), **S Schlüter** (Germany)

1: How to assess patient reported outcome (PRO)
  *PRO in IIM: Where do we stand – **C Mecoli** (USA)*
  *e-technologies in IIM – **O Landon-Cardinal** (Canada)*

2: 1h Q&A with patients

16:00 – 16:45
Snack Break and Exhibition
Poster Session II (P.045-074)
Juvenile dermatomyositis (P.045-063)
Immune-mediated necrotizing myopathy (P.064-074)

16:45 – 20:00
**Team Workshop jDM** – **K Adelan** (USA), **L Rider** (USA)

1: Medication usage and outcomes in jDM – **T Kishi** (Japan)

2: Insights from genomic analyses of jDM – **C Deakin** (UK)

3: Biomarkers of disease activity in jDM: Opportunities for personalised treatment strategies – **F v. Wijk** (The Netherlands)

4: Vasculopathy in jDM and work in progress – **C Gitiaux** (France)

5: Selected oral presentations

www.gcom2019.com
The use of metabolomics to develop novel biomarkers for juvenile dermatomyositis – J Dvergsten (USA)
Endothelial biomarker profiles reflect heterogeneity of juvenile dermatomyositis and may predict disease course – J Wienke (The Netherlands)
The relationship of pain, fatigue and emotional distress with quality of life in juvenile myositis – K Ardalan (USA)
Juvenile dermatomyositis – data of a national pediatric rheumatology database – C Sengler (Germany)

16:45 – 18:45
Speed Funding – Y Allenbach (France), H Chinoy (UK), A Kubota (Japan), A Meyer (France), D Pehl (UK), C Preuße (Germany), J Tanboon (Japan)
Presentation of the six finalists
Interferon-mediated impairment of myogenic precursors cells in dermatomyositis – L Gallay (France)
The pathogenesis and treatment of inclusion body myositis in a xenograft model – K Britson (USA)
Mechanisms underlying the therapeutic and iatrogenic response to glucocorticoids in skeletal muscle during inflammatory myopathies – M Giannini (France)
Inclusion body myositis on a chip – S Lassche (The Netherlands)
CD27-CXCR4hiCD21lo cells in Jo1-positive IIM – E Wilfong (USA)
Heart involvement and autoantibody profile in myositis – S Korsholm (Denmark)

Friday, 29 March 2019
08:30 – 10:00  IVA  Juvenile Dermatomyositis (jDM) – A Selva O’ Callagan (Spain), B Bader-Meunier (France)
08:30 – 08:55  1: Human type I interferonopathies – Y Crow (France)
08:55 – 09:20  2: The vasculopathy in jDM – D Eleftheriou (UK)
09:20 – 10:00  3: Selected oral presentations
Mitochondrial dysfunction: A novel treatment focus in juvenile dermatomyositis – M Wilkinson (UK)
Differential peripheral IFN score expression in juvenile dermatomyositis vs. Mendelian interferonopathies – H Kim (USA)
Juvenile inflammatory myopathy with anti-MDA5 auto-antibodies: A specific subgroup demonstrating differentially enhanced upregulation of interferon-alpha signaling – I Melki (France)

10:00 – 11:15  Coffee Break and Exhibition
Poster Session III (P.075-114)
Miscellaneous (P.075-114)

11:15 – 12:30  IVB  Dermatomyositis (DM) – M Fujimoto (Japan), V Werth (USA)
11:15 – 11:40  1: Ways to differentiate DM subtypes – W Stenzel (Germany)
11:40 – 12:30  2: Selected oral presentations
Identification of six dermatomyositis subgroups using principal component analysis-based cluster analysis – H Zhu (China)
Overexpression of type 1 IFN in skeletal muscle affects muscle function – M Morales (USA)
The role of low-density granulocytes (LDGs) and neutrophil extracellular traps (NETs) in the clinical profile of patients with idiopathic inflammatory myopathies – J Torres-Ruiz (Mexico)

Auto-antibodies targeting components of sarcolemma membrane repair: A pathogenic mechanism in inflammatory myopathies – W Jarjour (USA)

12:30 – 14:00 Lunch / Genzyme Industry Symposium

14:00 – 15:30 Immune-Mediated Necrotizing Myopathies (IMNM) – I Lundberg (Sweden), G Wang (China)

14:00 – 14:25 1: Macrophages - multidimensional players in inflammatory diseases – J Schultze (Germany)

14:25 – 14:50 2: Auto-antibodies at the center of IMNM pathogenesis – O Boyer (France)

14:50 – 15:30 3: Selected oral presentations

Investigating chaperone-mediated selective autophagy in immune-mediated necrotizing myopathies – N Fischer (Germany)

Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI – O Landon-Cardinal (Canada)

Role of MircoRNAs in immune-mediated necrotizing myopathy through regulation of myogenic differentiation-associated genes – Y Zuo (China)

15:30 – 16:30 Snack Break and Exhibition

Poster Session IV (P.115-151)

Sporadic inclusion body myositis (P.115-131)

Other forms of myositis (P.132-115)

16:30 – 17:00 IMACS Meeting – F Miller (USA), L Rider (USA)

17:00 – 17:30 Establishing a World Myositis Society: Where do we go from here? – J Schmidt (Germany)

18:30 Scientific Get-Together

Saturday, 30 March 2019

08:30 – 09:20 New Treatment Options – U Schneider (Germany), S Greenberg (USA)

08:30 – 08:55 1: How treatment of haematological malignancies paves the way for future treatment strategies for auto-immune and inflammatory diseases – O Hermine (France)

08:55 – 09:20 2: Next generation weapons for myositis: Biological or not? – R Aggarwal (USA)

09:20 – 10:00 Miscellaneous – O Boyer (France), J Lamb (UK)

Selected oral presentations

The interferon gene signature in dermatomyositis, the anti-synthetase syndrome, immune-mediated necrotizing myopathy, and inclusion body myositis: A comparative study – I Pinal-Fernandez (USA)

Evaluation of a novel particle-based assay for detection of myositis specific antibodies – K Malyavantham (USA)

Optimization of muscle NMR imaged segmentation to best discriminate disease progression in adult patients with inflammatory myopathies – H Reyngoudt (France)

10:00 – 10:30 Coffee Break, Exhibition

10:30 – 11:15 Hot Topics – HH Goebel (Germany), J Vencovský (Czech Republic)

Selected oral presentations

Identification of novel auto-antibodies for idiopathic inflammatory myopathies using human proteome microarray – L Li (China)

www.gcom2019.com
IFN level assessed by ultrasensitive detection technology in myositis patients: A promising biomarker of disease activity in dermatomyositis and anti-synthetase syndrome – L Bolko (France)

Analysis of muscle transcriptomic features in idiopathic inflammatory myopathies – H Chen (China)

11:15 – 12:00 IX Patients: Reports from patient association(s) – M Dimachkie (USA)

12:00 – 13:00 General Discussion, Prizes – T Lloyd (USA) & V Werth (Australia), Closing & Handover – O Benveniste (France), I Nishino (Japan) & W Stenzel (Germany)

13:15 – 14:30 Lunch